Literature DB >> 7212504

Increased clearance of propranolol in thyrotoxicosis.

J Feely, I H Stevenson, J Crooks.   

Abstract

The pharmacokinetics of oral propranolol were studied during chronic treatment in six patients when thyrotoxic and again when euthyroid. The mean total plasma propranolol steady-state concentration was 42% lower when the patients were thyrotoxic. After treatment of thyrotoxicosis there was a fall (P less than 0.05) in the oral clearance of both total (4.2 +/- 0.6 to 2.7 +/- 0.4 L/min, mean +/- SEM) and free (30.5 +/- 4.7 to 25.5 +/- 4.1 L/min) propranolol although the half-life of propranolol did not change significantly. The free fraction of propranolol was higher (p less than 0.05) in the thyrotoxic (14.2% +/- 1.3%) than in the euthyroid (11.4% +/- 0.8%) state. These results suggest that the pharmacokinetics of propranolol are significantly altered in thyrotoxicosis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7212504     DOI: 10.7326/0003-4819-94-4-472

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  7 in total

1.  Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease.

Authors:  M Pokrajac; D Simić; V M Varagić
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

3.  Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.

Authors:  R L Smith
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Altered plasma protein binding of drugs in thyroid disease.

Authors:  J Feely; I H Stevenson; J Crooks
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

6.  Nadolol in thyrotoxicosis.

Authors:  N R Peden; T E Isles; I H Stevenson; J Crooks
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 7.  Use of beta-adrenoceptor blocking drugs in hyperthyroidism.

Authors:  J Feely; N Peden
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.